TrialThe oncologist2020

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.

Richard F Riedel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.